Clinical Trial Update: 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the combination of Lutetium-177-PSMA-617 and olaparib in metastatic castration-resistant prostate cancer; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING